News

October 11, 2016 - ViaCyte to Present at Healthcare Events in October Read More

October 4, 2016 - Altor BioScience Corporation and NantKwest Inc. Announce Co-Development Agreement to Advance Innovative Natural Killer Cell Combination Immunotherapies for the Treatment of Cancer Read More

October 3, 2016 - THVD-102 Demonstrates Promising Potential as an Orally Administered Treatment for Hyperhidrosis Read More

October 3, 2016 - ViaCyte to Provide a Corporate Update at 2016 Cell and Gene Meeting on the Mesa Read More

September 9, 2016 - ViaCyte to Speak on Diabetes Panel at BioPharm America 2016 Read More

August 23, 2016 - DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial Read More

August 12, 2016 - ViaCyte to Present at Rejuvenation Biology 2016 Read More

August 4, 2016 - Torax Medical, Inc. Raises $25 Million in Series E Funding and Welcomes New Chief Commercial Officer Read More

July 21, 2016 - ViaCyte Awarded New CIRM Grant to Develop PEC-Direct for High-Risk Type 1 Diabetes Read More

July 19, 2016 - DalCor’s Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation Cardiovascular Genetics Read More